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Introduction
Upon anticancer drug treatment, a number of cellular stress response pathways is activated. Some of these pathways are linked to mitochondrial perturbations that are often associated with apoptosis. Thus, the release of pro-apoptotic factors from the intermembrane space into the cytosol, including cytochrome c, apoptosis inducing factor (AIF) and Smac/DIABLO, occurs after cytostatic treatment (1) (2) (3) (4) . The mechanisms regulating the release of cytochrome c include specific pore formation in the outer mitochondrial membrane and opening of the permeability transition pore (PTP) (reviewed by (5)). As a consequence of both the loss of the electrochemical gradient caused by pore opening and rupture of the outer mitochondrial membrane, the mitochondrial membrane potential (Dy) generally collapses.
There is general agreement that cytosolic cytochrome c interacts with apaf-1, ATP and procaspase-9 resulting in the activation of the latter, followed by caspase-3 activation and initiation of a proteolytic cascade (6) . However, the exact sequence of events resulting in disruption of mitochondrial function and release of cytochrome c from the mitochondria in apoptosis caused by anticancer drugs is not yet clear.
There are two prominent pathways that may cause mitochondrial dysfunction during apoptosis. First, death receptor activation through CD95/CD95L and caspase-8 activation during apoptosis is under several circumstances upstream from mitochondrial perturbations.
Thus, active caspase-8 may cause cleavage of the pro-apoptotic Bcl-2 member Bid and, as a consequence, mitochondrial dysfunction (7) (8) (9) . Several anticancer agents, including doxorubicin and etoposide, can upregulate CD95 and CD95L (10) (11) (12) . However, there is controversy on the relative importance of this pathway in anticancer drug-induced mitochondrial perturbations and apoptosis. Thus, in some cell types inhibition of this pathway using either FLIP, CrmA or dominant negative FADD, abrogates apoptosis whereas in other cell types little effect was observed (reviewed by (12) ). Although upregulation of death by guest on http://www.jbc.org/ Downloaded from 4 receptor pathway components was found in some solid tumor cell lines the extent of subsequent involvement of the mitochondrial pathway remains unclear (11, 13) . Upregulation and/or translocation of Bax and/or other pro-apoptotic Bcl-2 family members to the mitochondria is a second major pathway for mitochondrial perturbation preceding the onset of apoptosis. At the mitochondria, Bax invokes cytochrome c release and loss of Dy (14) , possibly via direct pore formation (15, 16) or by association with VDAC (17, 18) .
Importantly, the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-x L generally inhibit these mitochondrial perturbations (19, 20) . Various tumor cells have increased expression of proteins that inhibit either the death receptor pathways, e.g. FLIP, or apoptosis caused by Bax, e.g. Bcl-2 or Bcl-x L (21) (22) (23) (24) (25) . These tumor cells are generally more resistant to anticancer drug-induced apoptosis. It is unclear whether such resistance includes mitochondrial protection. Therefore, we have investigated the relative roles of caspase activation and Bcl-2-dependent pathways in mitochondrial perturbations and apoptosis caused by the anticancer drug doxorubicin.
Doxorubicin is often used in the treatment of solid tumors, including breast, liver and bone tumors (26) . It causes DNA damage and formation of reactive oxygen species, eventually resulting in apoptosis (27) . Although doxorubicin causes mitochondrial injury in cardiac muscle cells (28) and some other cell types, these effects were studied primarily in lymphoid cells (29, 30) . The molecular mechanism of mitochondrial injury and its role in the induction of apoptosis in adenocarcinoma cells remains however largely unclear. As discussed above, the dissipation of Dy is one of the markers for mitochondrial involvement in apoptosis. So far, dissipation of Dy caused by doxorubicin was determined either in the total cell population (30) (31) (32) or in 'viable' cells based on scatter properties (33) . These methods do not allow proper distinction of the exact cell population in which the changes in Dy occurred: genuinely viable, apoptotic or (secondary) necrotic cells. As a consequence, the identification by guest on http://www.jbc.org/ Downloaded from 5 of the exact sequence of events in doxorubicin-induced apoptosis was precluded. In the present study we set up three-color flow cytometry with rhodamine 123, annexin V-APC and propidium iodide to assess the involvement of the mitochondria in doxorubicin-induced apoptosis. For this purpose, we used the rat mammary adenocarcinoma cell line MTLn3, which is often used as a model to study molecular mechanisms of metastasis formation (34, 35 ) and responses to drug therapy both in vitro and in vivo (36) (37) (38) . We have previously characterized in detail the induction of apoptosis by anticancer drugs in these cells (38) .
In the present study, we show that the doxorubicin-mediated collapse of Dy is a primary event preceding PS externalization. Moreover, despite the fact that doxorubicin causes upregulation of CD95 and CD95L, prevention of caspase-8 activation does not prevent loss of Dy. Furthermore, although Bcl-2 inhibits apoptosis, dissipation of Dy is still observed. Analysis of Dy and cytochrome c localization on a cell-to-cell basis indicates that the collapse of Dy and cytochrome c release are mutually independent in both normal and Bcl-2 overexpressing cells. Together these data indicate that doxorubicin-induced dissipation of the mitochondrial membrane potential precedes PS externalization and is independent of a caspase-or Bcl-2-controlled checkpoint. 
Construction of Bcl-2 overexpressing cells
Subconfluent MTLn3 cells were transfected with pcDNA3 (Neo) or pcDNA3 containing human Bcl-2 (gift from Dr. James L. Stevens) using Lipofectamin Plus reagent and after reaching confluence they were selected for neomycin resistance (G418, 100 mg/ml).
For both vectors, three clones were selected and used for up to 6 passages during which they stably expressed Bcl-2 in over 95% of cells based on immunofluorescence.
In some experiments we used porcine renal proximal tubular cell line LLC-PK1 expressing either Bcl-2 (pkBCL-2 clone 6) or the empty vector (pkNEO clone 1) that have been described previously (39) . LLC-PK1 cells were cultured in Dubelco's Modified Eagle's Medium (DMEM) containing 10% (v/v) FBS and penicillin/streptomycin. For experiments cells were plated overnight in DMEM plus penicillin/streptomycin without FBS on collagen coated 6 cm culture dishes to form a subconfluent monolayer as described previously (40) .
Thereafter, cells were treated with varying concentrations of doxorubicin in DMEM/ penicillin/streptomycin for 24 hr. Caspase-3-like activity was determined as described previously (38) . Briefly, cells were trypsinized as described for AV/PI, washed once in PBS-EDTA and resuspended in lysis buffer (10 mM HEPES, 40 mM b-glycerophosphate, 50 mM NaCl, 2 mM MgCl 2 , 5 mM EGTA; pH 7.0). Cells were lysed by four cycles of freezing and thawing followed by centrifugation (30 min, 13000 g, 4 °C). To 10 mg cell lysate protein, 80 ml assay buffer was added (100 mM HEPES, 10% (w/v) sucrose, 0.1% (v/v) Nonidet P40, 10 mM dithiothreitol, 25 µM Ac-DEVD-AMC; pH 7.25) and the release of AMC was monitored (45 min, 37 °C) in a fluorescence plate reader (HTS 7000 Bio assay reader, Perkin Elmer, Norwalk, CT). Free AMC was used as a standard and caspase activity was expressed as pmol AMC/min/mg protein.
Determination of cell death
Determination of mitochondrial membrane potential
Mitochondrial membrane potential was essentially performed as described before (41, 42) with some modifications. Briefly, cells were harvested as described for AV/PI staining. (250 ng/ml)) in duplicate in 6-wells plates, as described by (35) . After one week, a toplayer of 2.5 ml of bottomagar was added. After 14 days, 150 ml of a 5 mg/ml MTT-solution in medium was added to the wells and after overnight incubation (37 °C), digital images of the wells were taken with a Nikon CCD camera. Colonies were counted using a particle-counting option in Image Pro (Media Cybernetics, Silver Spring, MD).
Immunoblotting
Attached cells were scraped in ice-cold TSE+ (10 mM Tris-HCl, 250 mM sucrose, 1 mM EGTA, pH 7.4, containing 1 mM dithiothreitol, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM sodium vanadate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride). 
Cytosolic fractions for cytochrome c immunoblotting
Cytosolic fractions were prepared as described by (46) . Briefly, floating cells in the medium and one wash of mitobuffer (50 mM PIPES-KOH (pH 7.4), 220 mM mannitol, 68 mM sucrose, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM dithiothreitol and 1 mM phenylmethylsulfonyl fluoride) were pelleted (5 min, 200 g, 4 °C) and pooled with attached cells scraped in 100 ml ice-cold mitobuffer. Cells were pelleted (1 min, 400 g, RT), resuspended in 100 ml mitobuffer and allowed to swell on ice for 30 min. Cells were homogenized by passing the suspension through a 25-gauge needle (10 strokes).
Homogenates were centrifuged (15 min, 13000 g, 4 °C) and supernatants were collected.
Thirty mg of cytosolic protein was separated on a 15% SDS-PAGE gel and transferred to 
Statistical analysis
Student's t test was used to determine if there was a significant difference between two means (p < 0.05). When multiple means were compared, significance was determined by one- The mitochondria are key organelles in the control of apoptosis. Therefore, we investigated the involvement of mitochondrial dysfunction in doxorubicin-induced apoptosis.
The mitochondrial membrane potential (Dy) is a sensitive measure for mitochondrial functioning (reviewed by (49)). Previously, we reported on the apoptotic effects of doxorubicin on MTLn3 cells (38) . Doxorubicin induced apoptosis in a time-dependent manner, as determined by Annexin V-staining, analysis of DNA content and caspase activity.
The onset of apoptosis occurred between 8 and 16 hr after exposure, with maximal caspase-3 activity at 24 hr.
In the present study, we analyzed Dy after doxorubicin treatment by flow cytometry using rhodamine 123 (Rho123). Initially, Rho123 fluorescence was only quantified in the PI- This enabled us to determine the relationship between loss of Dy and onset of apoptosis in PI -cells. Using confocal laser scanning microscopy (CLSM, Fig. 2 (Fig. 4) , that is also often used to determine the mitochondrial membrane potential in living cells (30, 44, 45) . We also investigated whether the collapse of Dy in MTLn3 cells was restricted to doxorubicin. The anticancer agent etoposide did not induce dissipation of Dy under conditions which resulted in comparable levels of apoptosis ( Fig. 3E and F) .
Doxorubicin-induced dissipation of Dy is independent of caspase activation.
Next we wanted to determine the mechanism for the early mitochondrial perturbations in doxorubicin-induced apoptosis. Upregulation of CD95/CD95L, which may occur in a p53-dependent manner, and subsequent activation of caspase-8 have been implicated in doxorubicin-induced apoptosis (12, 50, 51) . Therefore, we examined the kinetics of expression and/or cleavage of these proteins. Treatment of MTLn3 cells with doxorubicin rapidly induced upregulation of p53, CD95 and CD95L (Fig. 5A ). upregulation and caspase-8 activation.
Overexpression of Bcl-2 in MTLn3 cells inhibits doxorubicin-induced apoptosis.
If caspases are not involved in doxorubicin-induced collapse of Dy, which pathway(s) may then be responsible? Anti-apoptotic Bcl-2 family members, including Bcl-2 and Bcl-x L , inhibit apoptosis by preventing mitochondrial perturbations during the apoptotic process.
Therefore, we tested whether the decrease of Dy in genuinely viable cells upon doxorubicin treatment also occurred in MTLn3 cells overexpressing Bcl-2. We constructed MTLn3 cells stably overexpressing Bcl-2 and characterized the protective action of Bcl-2 in doxorubicininduced apoptosis. Three different clones were obtained which all showed strong overexpression of Bcl-2 (Fig. 6A) . Immunofluorescent staining for Bcl-2 together with the mitochondrial marker Mitotracker red (CMXRos), indicated that most of the Bcl-2 was located at the mitochondria (Fig. 6A) . Very little Bcl-2 staining was detectable in Neo control cells. In Bcl-2 overexpressing (Bcl-2) cells, doxorubicin did not induce statistically significant DNA fragmentation at concentrations up to 25 mM whereas in Neo control cells 39% apoptosis was observed (Fig. 6B) . DNA-fragmentation is a late, caspase-dependent event in apoptosis. Therefore, we also determined the effect of Bcl-2 overexpression on caspase activation. Doxorubicin caused a clear induction of caspase-3-like activity in Neo cells (control: 156 ± 11 vs. doxorubicin: 528 ± 76 pmol DEVD-AMC/min/mg protein).
Although some induction of caspase activity was observed in Bcl-2 cells (control: 25 ± 11 vs.
doxorubicin: 120 ± 6 pmol DEVD-AMC/min/mg protein), the absolute activity was less than 25 % of doxorubicin-treated Neo cells.
In a previous report (38) we demonstrated that inhibition of caspases using zVADfmk did not completely block doxorubicin-induced PS externalization in MTLn3 cells. This indicated that part of the PS externalization occurred in a caspase-independent, possibly Bcl-2 sensitive manner. Therefore, we next investigated whether Bcl-2 was able to block doxorubicin-induced PS externalization. While inhibition of caspases reduced DNAfragmentation to control levels in Neo cells (Fig. 7A ), PS externalization caused by doxorubicin treatment was only marginally affected by zVAD-fmk (Fig. 7B) . In contrast, Bcl-2 overexpression protected against DNA-degradation as well as PS externalization induced by doxorubicin (Fig. 7) . zVAD-fmk had only a slight additional protective effect on DNA fragmentation but it had no effect on PS externalization. Importantly, while the resistance of Bcl-2 cells to doxorubicin was not due to inhibition of the induction of p53, CD95 or CD95L expression, caspase-8 and caspase-3 activation were markedly reduced in Bcl-2 cells (Fig. 7C) . The inhibition of caspase-8 cleavage in Bcl-2 cells further strenghens the notion that caspase-8 cleavage occurs secondary to mitochondrial perturbations. These observations indicate clear differences in the regulation of several apoptotic features in doxorubicin-induced apoptosis by Bcl-2 on the one hand and caspases on the other hand.
Bcl-2 does not protect against doxorubicin-induced dissipation of Dy.
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In many cell types Bcl-2-mediated protection against apoptosis is associated with preservation of mitochondrial homeostasis (19) . Since Bcl-2 protected against PS externalization, we next checked whether Bcl-2 could also prevent the decrease in Dy As expected LLC-PK1 cells stably transfected with Bcl-2 (pkBcl2 clone 6) were resistant to doxorubicin-induced apoptosis compared to empty vector control cells (pkNEO clone 1). In addition, cells that were not yet apoptotic after doxorubicin treatment (e.g. AV-/PI-cells) had a decreased Dy (Table I) . z-VADfmk did block the doxorubicin-induced apoptosis of pkNEO and pkBcl2 cells, however, no protection was observed against the decrease of Dy (Table I ).
In conclusion, these data indicate that the dissipation of Dy caused by doxorubicin is an event that occurs upstream of a checkpoint controlled by either the Bcl-2 family or caspases.
Bcl-2 does not protect against longterm survival of MTLn3 cells after doxorubicin treatment.
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Bcl-2 clearly protected against doxorubicin-induced apoptosis. However, the fact that no protection was observed against the doxorubicin-induced dissipation of the mitochondrial membrane potential suggested that compromised mitochondrial function may affect longterm survival. Indeed, in MTLn3 cells overexpressing Bcl-2, doxorubicin still caused a strong reduction in clonogenic survival in a soft-agar assay (Fig. 9) .
Cytochrome c release is not strictly correlated with loss of Dy.
Cytochrome c release from the mitochondria is a critical event in formation of the apoptosome and subsequent activation of caspase-9 and -3 (6). In our cells the doxorubicin- 10A ). Exposure to doxorubicin caused a decreased staining of CMXRos; in some cells no mitochondrial localization of CMXRos was evident (arrowhead). Also the punctuate localization of cytochrome c staining was lost ( Fig. 10A ; arrowhead and asterisk), which was evident in approximately 15 % of the cells (Fig. 10B) . To determine whether this cytochrome c translocation correlated with dissipation of Dy, we further discriminated between cells with high or low Dy. This revealed that cytochrome c release was not strictly correlated with loss of Dy, since also cells with still high Dy showed cytochrome c release, although to a lesser extent than cells with low Dy (Table II) In contrast, staurosporin (50 nM, 6 hr) was capable of induction of caspase-3 activation prior to cell detachment, probably due to the rapid induction of apoptosis (data not shown).
Bcl-2 only partially inhibits the release of cytochrome c.
Next we investigated the protective role of Bcl-2 against doxorubicin-induced release of cytochrome c. Despite the fact that Bcl-2 protected against apoptosis, doxorubicin induced cytochrome c release in cells that were still attached to a similar extent in Bcl-2 cells as in Neo cells (Fig. 10A and B) . Also in Bcl-2 cells there was no direct correlation between loss of Dy and cytochrome c release as in Neo cells ( Fig. 10A and Table II Secondly, cellular damage may also result in upregulation or posttranslational modification of several pro-apoptotic Bcl-2 family members that directly affect mitochondrial membrane integrity, e.g. Bax upregulation and translocation to the mitochondria or Bad phosphorylation (57) (58) (59) . The consensus is that this pathway acts independent of caspase-8 activation and is generally inhibited by Bcl-2 overexpression (20) . Thirdly, the effect of doxorubicin in MTLn3 cells may be a direct effect of doxorubicin on the mitochondria as has been observed in isolated mitochondria from heart and liver (28, 60) .
CD95 activation would exert its effect through caspase-8 activation and Bid cleavage, which may engage the mitochondria. In MTLn3 cells, doxorubicin caused upregulation of 22 CD95 and CD95L. However, since zVAD-fmk prevented caspase-8 activation (Fig. 5B) whithout affecting the mitochondrial perturbations, the CD95/CD95L/caspase-8 pathway plays a minor role in the observed loss of Dy. The fact that zVAD-fmk does not inhibit the dissipation of Dy also argues against a feedback mechanism in which a moderate release of cytochrome c would activate caspase-3, which in turn affects the mitochondria, thereby enhancing loss of Dy and/or further release of cytochrome c (61-63).
Overexpression of Bcl-2 and Bcl-x L inhibits apoptosis induced by a variety of stimuli, in particular those that utilize the mitochondria-dependent pathway (20, 64) . This is often Our data indicate that Bcl-2 was able to inhibit doxorubicin-induced apoptosis despite the fact that some cytochrome c release was observed at 16 hours after exposure. This appears to be comparable with the observation that Bcl-2 overexpression markedly reduced apoptosis caused by microinjection of cytochrome c. Such an effect may be mediated by sequestration of procaspase-9 by Bcl-2, thereby inhibiting formation of the apoptosome and activation of caspase-3 (72) (73) (74) (75) (76) (77) .
In MTLn3 cells, Bcl-2 overexpression clearly protected against doxorubicin-induced DNA fragmentation as well as PS externalization. Interestingly, zVADfmk only partially protected against PS externalization (38) . This strongly suggests that PS externalization caused by doxorubicin is largely caused by a caspase-independent pathway that is inhibitable MTLn3 cells were treated with doxorubicin as described in Fig. 1 and stained for DiOC 6 , annexin V and PI prior to analysis by flow cytometry as described in the Experimental procedures section. Data shown are the mean of three independent experiments ± SE.
Characters indicate statistical significance as described in Experimental procedures. by guest on 
